Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 99

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 99
---
 as of June 16, 2025 (the “ Signing Date”), and made by and among MIRA Pharmaceuticals, Inc., a Florida corporation (the “ Company”), MIRAPHARM Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub”), and SKNY Pharmaceuticals, Inc., a Delaware corporation (“ SKNY”). Terms not otherwise defined herein shall have the meanings ascribed to such terms in Section ‎8.9of this Agreement.

<div align='center'>RECITALS</div>

WHEREAS, the respective boards of directors of the Company (the “ Company Board”), the Merger Sub (the “ Merger Sub Board”) and SKNY(the “ SKNY Board”) have approved, and declared advisable, fair to and in the best interests of each such entity and its respective stockholders to enter into this Agreement and to perform and execute the transactions contemplated by this Agreement, including the merger of SKNY with and into Merger Sub, with the SKNY being the surviving entity (the “ Merger”), upon the terms and subject to the conditions set forth in this Agreement and in accordance with the provisions of Section 251 of the Delaware General Corporations Law (“ DGCL”);

WHEREAS, in connection with the Merger, each holder of shares of common stock, par value $0.001 per share, of SKNY (“ SKNY Common Stock”) as of immediately prior to the Effective Time shall be entitled to receive shares of Common Stock, par value $0.0001 per share of the Company at the exchange ratio set forth on Schedule A hereto (the “ Exchange Ratio” and the “ Company Common Stock”) for each share of SKNY Common Stock held by such stockholder;

WHEREAS, each of the Merger Sub Board and the SKNY Board intends to recommend that the stockholders of Merger Sub and SKNY, respectively, approve and adopt this Agreement and the Merger;

WHEREAS, each of the Company, Merger Sub and SKNY wish hereby to make certain representations, warranties, covenants, and agreements in connection with the Merger and also to prescribe various conditions to the Merger; and

WHEREAS, for U.S. federal income Tax purposes, the Parties intend that the Merger qualify as a tax-free contribution pursuant to Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”).

NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants,